| Literature DB >> 28566589 |
Tomonori Ida1, Masahiko Inamori2, Yumi Inoh3, Koji Fujita3, Jun Hamanaka1, Hideyuki Chiba1, Akihiko Kusakabe4, Taiki Morohashi1, Toru Goto1, Shin Maeda5.
Abstract
Objective The risk factors associated with severe erosive esophagitis are not well defined in Japan. We aimed to evaluate the risk factors associated with the endoscopic severity of esophageal mucosal injury. Methods Eighty consecutive Japanese patients with severe erosive esophagitis [Los Angeles (LA) classification grade C or D] who had undergone upper endoscopies in the Gastroenterology Division of Omori Red Cross Hospital between June 2010 and March 2013 were retrospectively analyzed. For each case, a control with mild erosive esophagitis (LA classification grade A or B) who was matched by sex and age was randomly selected during the same period. Among the endoscopic findings, the condition of the gastroesophageal flap valve (GEFV) was graded according to Hill's classification. We identified the risk factors for severe erosive esophagitis using a multivariable logistic regression model. Results A poor performance status (PS) (odds ratio [OR]=17.1201, 95% confidence interval [CI]=3.0268-140.3121, p=0.0008) and an abnormal GEFV (OR=3.0176, 95% CI=1.0589-9.4939, p=0.0385) were risk factors for severe erosive esophagitis, while the presence of open-type gastric mucosal atrophy (GMA) was inversely associated with severe erosive esophagitis (OR=0.2772, 95% CI=0.1087-0.6675, p=0.0040). Conclusion Among patients with erosive esophagitis, a poor PS and an abnormal GEFV were associated while GMA was inversely associated with severe erosive esophagitis. Drug therapy alone or in combination with physical therapy may improve the therapeutic effect on severe erosive esophagitis in patients with a poor PS.Entities:
Keywords: gastroesophageal flap valve; risk factor; severe erosive esophagitis
Mesh:
Year: 2017 PMID: 28566589 PMCID: PMC5498190 DOI: 10.2169/internalmedicine.56.8058
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure.Retroflexed view of the gastroesophageral flap valve. (a) Grade I. The prominent fold of tissure along the lesser curvature was closely apposed to the endoscope. (b) Grade II. The fold was present but there would be periods of opening and rapid closing around the endoscope. (c) Grade III. The fold was not prominent and the endoscope was not gripped tightly by the ridge. (d) Grade IV. There was no fold and the lumen of the esophagus gaped open, allowing the squamous epithelium to be viewed below.
Clinical Characteristics of the Patients with Severe EE (n=80) and with Mild EE as the Control (n=80).
| Sever EE (n=80) | Control (n=80) | p value | |
|---|---|---|---|
| Age: median (range) in years | 74.0 (40.0-96.0) | 74.0 (40.0-96.0) | 1.0000 |
| Sex: male; n (%) | 53 (66.25) | 53 (66.25) | 1.0000 |
| PS: n (%) | |||
| 0 | 39 (48.8) | 63 (78.8) | |
| 1 | 15 (18.8) | 11 (13.8) | |
| 2 | 5 (6.3) | 3 (3.8) | 0.0002 |
| 3 | 11 (13.8) | 0 | |
| 4 | 10 (12.5) | 3 (3.8) | |
| PS 3 or 4: n (%) | 21 (26.3) | 3 (3.8) | <0.0001 |
| Gibbus: n (%) | 19 (23.8) | 9 (11.3) | 0.0375 |
| Heartburn symptoms: n (%) | 42 (52.5) | 42 (52.5) | 1.0000 |
| Gastrointestinal bleeding signs: n (%) | 30 (37.5) | 4 (5.0) | <0.0001 |
| BMI: median (range) | 21.9 (14.6 - 35.5) | 23.0 (16.4 - 36.0) | 0.0191 |
| Current smoker: n (%) | 29 (36.3) | 20 (25.0) | 0.1227 |
| Brinkman index: mean (range) | 301.5 (0 - 2,880) | 235 (0 - 1,660) | 0.3830 |
| Heavy drinker: n (%) | 19 (23.8) | 16 (20.0) | 0.5662 |
| Blood examination | |||
| Hb: mean (median) (g/dL) | 11.7 (12.1) | 13.2 (14.1) | 0.0013 |
| CRP (mg/dL) | 2.330 (0.825) | 0.384 (0.070) | <0.0001 |
BMI: Body mass index
CRP: C-reactive protein
Prevalence of Comorbidities in Patients with Severe EE and the Control Group.
| Comorbidities | Sever EE (n=80) | Control (n=80) | p value |
|---|---|---|---|
| Diabetes: n (%) | 18 (22.5) | 19 (23.8) | 0.8513 |
| Hypertension: n (%) | 28 (35.0) | 33 (41.3) | 0.4157 |
| Asthma: n (%) | 3 (3.8) | 2 (2.5) | 0.6496 |
| Chronic renal failure: n (%) | 4 (5.0) | 4 (5.0) | 1.0000 |
| Chronic heart failure: n (%) | 6 (7.5) | 7 (8.8) | 0.7723 |
| Ischemic heart disease: n (%) | 5 (6.3) | 1 (1.3) | 0.0960 |
| Cerebrovascular disease: n (%) | 14 (17.5) | 12 (15.0) | 0.6682 |
| Gastroduodenal ulcer: n (%) | 16 (20.0) | 17 (21.3) | 0.8451 |
| COPD: n (%) | 5 (6.3) | 1 (1.3) | 0.0960 |
| Neurodegenerative disease: n (%) | 6 (7.5) | 6 (7.5) | 1.0000 |
| Dementia: n (%) | 10 (12.5) | 2 (2.5) | 0.0163 |
| Arrhythmia: n (%) | 2 (2.5) | 4 (5.0) | 0.4053 |
| Depression: n (%) | 5 (6.3) | 8 (10.0) | 0.3854 |
| Osteoporosis: n (%) | 6 (7.5) | 4 (5.0) | 0.5136 |
| Liver cirrhosis: n (%) | 3 (3.8) | 1 (1.3) | 0.3112 |
COPD: chronic obstructive pulmonary disease
Prevalence of Medicational Risk Factor in Patients with Severe EE and the Control Group.
| Medications | Sever EE (n=80) | Control (n=80) | p value |
|---|---|---|---|
| PPI: n (%) | 25 (31.3) | 14 (17.5) | 0.0428 |
| NSAIDs: n (%) | 14 (17.5) | 8 (10.0) | 0.1684 |
| Steroids: n (%) | 5 (6.3) | 1 (1.3) | 0.0960 |
| Bisphosphonates: n (%) | 5 (6.3) | 4 (5.0) | 0.7315 |
| Calcium blockers: n (%) | 16 (20.0) | 24 (30.0) | 0.1441 |
| ACE inhibitors: n (%) | 19 (23.8) | 19 (23.8) | 1.0000 |
| β-blockers: n (%) | 5 (6.3) | 2 (2.5) | 0.2462 |
| Nitrites: n (%) | 4 (5.0) | 3 (3.8) | 0.6991 |
| Xanthines: n (%) | 2 (2.5) | 0 (0) | 0.1547 |
| Sulfonylureas: n (%) | 7 (8.8) | 7 (8.8) | 1.0000 |
| Anti-thrombotic medicines including low-dose aspirin: n (%) | 20 (25.0) | 19 (23.8) | 0.8539 |
| Cerebral nerve and antipsychotic drugs: n (%) | 16 (20.0) | 15 (18.8) | 0.8415 |
PPI: proton pump inhibitor
ACE: angiotensin-converting enzyme
Endoscopic Findings
| Endoscopic findings | Sever EE (n=80) | Control (n=80) | p value |
|---|---|---|---|
| Esophageal complications | |||
| Bleeding: n (%) | 15 (18.8) | 0 | <0.0001 |
| Stenosis: n (%) | 7 (8.8) | 0 | 0.0068 |
| Ulcer: n (%) | 27 (33.8) | 0 | <0.0001 |
| GMA open type: n (%) | 22 (27.5) | 46 (57.5) | 0.0001 |
| Hill’s grade: n (%) | |||
| I | 0 | 2 (2.5) | <0.0001 |
| II | 9 (11.2) | 28 (35.0) | |
| III | 27 (33.8) | 31 (38.8) | |
| IV | 44 (55.0) | 19 (23.7) | |
| Hill’s grades III and IV: n (%) | 71 (88.8) | 50 (62.5) | 0.0001 |
| Barrett’s epithelium: n (%) | 56 (70.0) | 22 (27.5) | <0.0001 |
GMA: gastromucosal atrophy
Multiple Logistic Regression Analysis Using Parameters with a p value of Less than 0.1 Identified from Univariate Regression Analysis.
| Clinical factors | Odds ratio | 95% CI | p value |
|---|---|---|---|
| PS 3 and 4 | 17.1201 | 3.0268 - 140.3121 | 0.0008 |
| Hill’s grades III and IV | 3.0176 | 1.0589 - 9.4939 | 0.0385 |
| GMA: open type | 0.2772 | 0.1087 - 0.6675 | 0.0040 |
| Gastrointestinal bleeding signs | 4.3351 | 1.2074 - 18.5115 | 0.0239 |
| CRP | 1.8122 | 0.3251 - 0.8621 | 0.0053 |
| Barrett’s epithelium: n (%) | 9.6271 | 3.9626 - 25.7395 | <0.0001 |
| Gibbus | 0.2796 | 0.0528 - 1.2856 | 0.1027 |
CI: confidence interval